ProMIS Neurosciences announced full enrollment of 144 patients in its Phase 1b PRECISE-AD trial for Alzheimer's disease, with six-month assessments expected by Q2 2026 and interim analysis in early Q3 2026. Their lead candidate, PMN310, shows a favorable safety profile with no serious treatment-related adverse events reported. The company secured $75.5 million in financing in early 2026 to support ongoing development, including a subcutaneous formulation of PMN310. Top-line data from the trial is anticipated in early 2027, potentially advancing PMN310 toward a registrational study pending FDA feedback.
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Industrial Development Funding (IDF) and Oaktree have committed $1.7 billion to support Bloom Energy's fuel cell technology for building AI cloud infrastructure for Nebius. This project will provide dedicated behind-the-meter power to meet the high c...
